Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families w...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2007
|
| _version_ | 1797066184151007232 |
|---|---|
| author | Foster, C Watson, M Eeles, R Eccles, D Ashley, S Davidson, R Mackay, J Morrison, P Hopwood, P Evans, D |
| author_facet | Foster, C Watson, M Eeles, R Eccles, D Ashley, S Davidson, R Mackay, J Morrison, P Hopwood, P Evans, D |
| author_sort | Foster, C |
| collection | OXFORD |
| description | This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families with a known BRCA1/2 mutation. One hundred and ninety-three out of 285 (70% response) participants at nine UK clinical genetics centres completed assessments at 3 years: 80% female; 37% carriers of a BRCA1/2 mutation. In the 3 years, post-genetic testing carriers reported more risk management activities than non-carriers. Fifty-five per cent of female carriers opted for risk reducing surgery; 43% oophorectomy; and 34% mastectomy. Eighty-nine per cent had mammograms compared with 47% non-carriers. Thirty-six per cent non-carriers > or =50 years did not have a mammogram post-test. Twenty-two per cent male carriers had colorectal and 44% prostate screening compared with 5 and 19% non-carriers respectively. Seven per cent carriers and 1% non-carriers developed cancer. Distress levels did not differ in carriers and non-carriers at 3-year follow-up. Forty per cent of female carriers reported difficulties with life and/or health insurance. Given the return to pre-test levels of concern among female non-carriers at 3 years and a substantial minority not engaging in recommended screening, there appears to be a need to help some women understand the meaning of their genetic status. |
| first_indexed | 2024-03-06T21:38:47Z |
| format | Journal article |
| id | oxford-uuid:472e24a3-8543-469a-8571-787d6bd04e53 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:38:47Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:472e24a3-8543-469a-8571-787d6bd04e532022-03-26T15:18:29ZPredictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:472e24a3-8543-469a-8571-787d6bd04e53EnglishSymplectic Elements at Oxford2007Foster, CWatson, MEeles, REccles, DAshley, SDavidson, RMackay, JMorrison, PHopwood, PEvans, DThis prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families with a known BRCA1/2 mutation. One hundred and ninety-three out of 285 (70% response) participants at nine UK clinical genetics centres completed assessments at 3 years: 80% female; 37% carriers of a BRCA1/2 mutation. In the 3 years, post-genetic testing carriers reported more risk management activities than non-carriers. Fifty-five per cent of female carriers opted for risk reducing surgery; 43% oophorectomy; and 34% mastectomy. Eighty-nine per cent had mammograms compared with 47% non-carriers. Thirty-six per cent non-carriers > or =50 years did not have a mammogram post-test. Twenty-two per cent male carriers had colorectal and 44% prostate screening compared with 5 and 19% non-carriers respectively. Seven per cent carriers and 1% non-carriers developed cancer. Distress levels did not differ in carriers and non-carriers at 3-year follow-up. Forty per cent of female carriers reported difficulties with life and/or health insurance. Given the return to pre-test levels of concern among female non-carriers at 3 years and a substantial minority not engaging in recommended screening, there appears to be a need to help some women understand the meaning of their genetic status. |
| spellingShingle | Foster, C Watson, M Eeles, R Eccles, D Ashley, S Davidson, R Mackay, J Morrison, P Hopwood, P Evans, D Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. |
| title | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. |
| title_full | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. |
| title_fullStr | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. |
| title_full_unstemmed | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. |
| title_short | Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. |
| title_sort | predictive genetic testing for brca1 2 in a uk clinical cohort three year follow up |
| work_keys_str_mv | AT fosterc predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT watsonm predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT eelesr predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT ecclesd predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT ashleys predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT davidsonr predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT mackayj predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT morrisonp predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT hopwoodp predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup AT evansd predictivegenetictestingforbrca12inaukclinicalcohortthreeyearfollowup |